Wolfe starts Merck at Peer Perform, notes competitive overhangs
Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is ...
Merck initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. Published first on TheFly – the ultimate source for ...
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Merck KGaA Earnings Growth Beats Expectations — Update
The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...
Reuters22h
Merck KGaA Q3 earnings rise faster than expected on lower costs
FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...